Gamunex Is the Preferred Liquid IGIV Therapy Among Allergists and Immunologists Surveyed
The national blinded survey, conducted by Harris Interactive(R) on behalf of Talecris Biotherapeutics between December 17, 2006 and January 9, 2007, included more than 350 practicing allergy and immunology specialists, selected from the American Medical Association (AMA) Physician Master List, who currently prescribe IGIV products.
Erwin Gelfand, M.D., Chairman of the Department of Pediatrics at the National Jewish Medical and Research Center in Denver, commented on the results of the survey. "This new preference information reinforces our experience that not all IGIV products are the same. Differences in manufacturing processes and formulations can affect patients' clinical outcomes. That is why Gamunex(R) is the preferred IGIV in our infusion center."
"Beginning with the introduction of the first ready-to-use liquid IGIV product in 1981, Talecris has a 25-year commitment of investments toward technological innovations to advance liquid IGIV therapy," said Alberto Martinez, M.D., President and CEO of Talecris Biotherapeutics. "Gamunex(R) represents our continuing commitment to this history of innovation and serving the IGIV community."
Results demonstrating preference for Gamunex(R) among liquid IGIV brands included within an overall list of leading liquid and non-liquid IGIV brands are statistically significant with a 95% confidence interval (indicating that there is no more than a five in 100 chance that the observed differences could have been obtained by chance) and are based on a blinded, national survey of 358 allergists/immunologists from the AMA Physician Master List. The survey was conducted by Harris Interactive(R) on behalf of Talecris Biotherapeutics from December 17, 2006 to January 9, 2007. In order to qualify to complete the survey, the allergists/immunologists must have been in practice for at least one year, be active prescribers of IGIV, and be aware of at least two brands of IGIV. Respondents were asked to assume no difference in terms of availability, cost, and reimbursement when indicating their most preferred IGIV brand. The survey was conducted and the results are validated by a reputable, independent, third-party, Harris Interactive(R), a worldwide market research and consulting firm best known for the Harris Poll(R).
Gamunex(R) is a lifesaving IGIV therapy that contains antibodies purified from the donated blood plasma of thousands of people and is used to treat a variety of health problems, both as a means of immune replacement and for modulating the immune system. Gamunex(R) is indicated as replacement therapy of primary humoral immunodeficiency disease (PI) and as immunomodulatory therapy for idiopathic thrombocytopenic purpura (ITP).
Important Safety Information
Gamunex(R) is contraindicated in individuals with known anaphylactic or severe systemic response to Immune Globulin (Human). Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis and death. Patients should be instructed to immediately report symptoms of decreased urine output, sudden weight gain, fluid retention/edema, and/or shortness of breath (which may suggest kidney damage) to their physicians. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number. Gamunex(R) does not contain sucrose. Glycine, a natural amino acid, is used as a stabilizer.
There have been reports of noncardiogenic pulmonary edema, rare reports of hemolytic anemia, and very rare reports of aseptic meningitis in patients administered with IGIV. Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity. The most common side effects noted during clinical trials included headache, vomiting, fever, nausea, rash, and back pain.
As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.
For additional information about Gamunex(R), please see accompanying Full Prescribing Information.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, which earned revenues exceeding $1 billion through the year ending June 30, 2006, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 3,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com or www.talecrisplasma.com.
About Harris Interactive(R)
Harris Interactive(R) is the 12th largest and fastest-growing market research firm in the world. The company provides innovative research, insights and strategic advice to help its clients make more confident decisions which lead to measurable and enduring improvements in performance. Harris Interactive(R) is widely known for The Harris Poll, one of the longest running, independent opinion polls and for pioneering online market research methods. The company has built what it believes to be the world's largest panel of survey respondents, the Harris Poll Online. Harris Interactive(R) serves clients worldwide through its United States, Europe, and Asia offices, its wholly-owned subsidiary Novartis in France, and through a global network of independent market research firms. The service bureau, HISB, provides its market research industry clients with mixed-mode data collection, panel development services as well as syndicated and tracking research consultation. More information about Harris Interactive(R) may be obtained at www.harrisinteractive.com.
Lacy McMahon, 919-316-6316
Posted: February 2007